68Ga-P3 PET/CT Imaging in Malignancy
Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that consists of 750 amino acids. It is highly expressed on most prostate cancer cells and neovascular endothelial cells of tumors, making PSMA a highly specific and significant imaging target for malignancies. \[68Ga\]P3, a novel molecul
| Condition(s) | Neoplasms |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that consists of 750 amino acids. It is highly expressed on most prostate cancer cells and neovascular endothelial cells of tumors, making PSMA a highly specific and significant imaging target for malignancies. \[68Ga\]P3, a novel molecular probe of PET imaging agent that targets PSMA, can be used in the diagnosis and research of a wide variety of PSMA high-expression malignanciesr. |
| Who can participate | Inclusion Criteria: patients with confirmed or suspected cancer; 18F-FDG PET/CT within 1 week; Signed written informed consent Exclusion Criteria: Pregnant and lactating women; Female patients plan to become pregnant within 6 months. |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | Peking University First Hospital |
| Locations | Beijing, Beijing Municipality, China |
| Start date | 2023-05-20 |
| NCT ID | NCT05887687 |
| Official listing | https://clinicaltrials.gov/study/NCT05887687 |